Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $93,000.

  • Janux Therapeutics' Capital Expenditures rose 272.00% to $93,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $979,000, marking a year-over-year increase of 17.67%. This contributed to the annual value of $359,000 for FY2024, which is 80.59% down from last year.
  • Per Janux Therapeutics' latest filing, its Capital Expenditures stood at $93,000 for Q3 2025, which was down 80.34% from $473,000 recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Capital Expenditures registered a high of $2.5 million during Q3 2022, and its lowest value of $25,000 during Q3 2024.
  • Its 3-year average for Capital Expenditures is $286,000, with a median of $371,000 in 2025.
  • Per our database at Business Quant, Janux Therapeutics' Capital Expenditures spiked by 62,800.00% in 2021 and then plummeted by 94.68% in 2024.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Capital Expenditures stood at $629,000 in 2021, then spiked by 226.87% to $2.1 million in 2022, then crashed by 74.95% to $515,000 in 2023, then crashed by 91.84% to $42,000 in 2024, then spiked by 272.00% to $93,000 in 2025.
  • Its Capital Expenditures stands at $93,000 for Q3 2025, versus $473,000 for Q2 2025 and $371,000 for Q1 2025.